{"id":"W1977983810","doi":"10.1016/s0960-9776(11)70295-8","title":"Reappraising antiangiogenic therapy for breast cancer","year":2011,"lang":"en","type":"review","venue":"The Breast","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; National Health Research Institutes; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; National Institute for Health and Care Research; Canada Research Chairs; GlaxoSmithKline; Pfizer Canada; Cancer Research Institute","keywords":"Medicine; Bevacizumab; Sunitinib; Breast cancer; Oncology; Chemotherapy; Metastatic breast cancer; Internal medicine; Cancer; Angiogenesis; Trastuzumab; Clinical trial; Pharmacology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002503609,0.0004368348,0.0006590312,0.00004353485,0.000182605,0.00003570756,0.0006226088,0.0003570015,0.0001814309],"category_scores_gemma":[0.00000425543,0.0002599806,0.001119499,0.0001295762,0.0001224813,0.000002769142,0.0001148288,0.00009871154,0.00002418265],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002464504,"about_ca_system_score_gemma":0.0003376441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009080565,"about_ca_topic_score_gemma":0.00002037936,"domain_scores_codex":[0.9985657,0.00009562186,0.0003298422,0.0005178089,0.00009237891,0.000398609],"domain_scores_gemma":[0.9987758,0.00002417678,0.0002859505,0.0007315781,0.0001077769,0.0000747211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007058227,0.00003226853,0.00001145587,0.0005315622,0.0005670893,4.452884e-7,0.0000116642,2.635683e-7,0.0001362471,0.00007614939,0.007183968,0.9913783],"study_design_scores_gemma":[0.0002113877,0.00004235428,0.0001001633,0.000948387,0.0004328421,0.0005593012,0.000005715029,5.989123e-7,0.00006236698,0.00001383861,0.9972522,0.0003708825],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000316087,0.9960998,0.0001865527,0.00007883822,0.0004003569,0.0007843377,0.002002369,0.00001722252,0.0003989206],"genre_scores_gemma":[0.0002213016,0.99512,0.0000589119,0.0001701282,0.002395958,0.0004903767,0.0002756927,0.0001336359,0.001133935],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9910074,"threshold_uncertainty_score":0.9999852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05578876287634275,"score_gpt":0.3466847822153159,"score_spread":0.2908960193389731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}